Abstract 323P
Background
Ovarian cancer is a general phrase that may be applied to any malignancy that affects the ovaries and is one of the worst malignancies. Aside from the number of its population, the Asian population also has a very diverse culture and socioeconomic development. Pretreatment peripheral blood cell counts, including lymphocytes, monocytes, and neutrophils, are major prognostic indicators in various cancers. This study aimed to evaluate the role of NLR, PLR, and LMR as prognostic biomarkers in ovarian cancer among the Asian population in a meta-analysis design.
Methods
This study assessed the association between NLR, PLR, and LMR and ovarian cancer as prognostic biomarkers based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. The literature research was performed by systematically searching PubMed, ScienceDirect, and Google Scholar using the search terms based on BOOLEAN operators. Revman software ver 5.4.1 was employed for all statistical analyses, and p-values<0.05 were considered statistically significant.
Results
This study included 17 studies conducted in various Asian countries according to inclusion and exclusion criteria. Significant results were found in both univariate and multivariate analysis for NLR, PLR, and LMR to overall survival [(Univariate) NLR: HR 2.04; 95% CI 1.61 – 2.58; p<0.001, PLR: HR 2.04; 95% CI 1.26 – 3.30; p<0.001, LMR: HR 0.53; 95% CI 0.40 – 0.72; p<0.001. (Multivariate) NLR: HR 1.65; 95% CI 1.22 – 2.22; p<0.001, PLR: HR 2.12; 95% CI 1.70 – 2.66; p<0.001, LMR: HR 0.54; 95% CI 0.37 – 0.80; p=0.002]. Significant results were also found in both univariate and multivariate analysis for NLR and PLR to disease-free survival [(Univariate) NLR: HR 2.19; 95% CI 1.36 – 3.54; p<0.001, PLR: HR 1.95; 95% CI 1.31 – 2.91; p<0.001. (Multivariate) NLR: HR 1.37; 95% CI 1.21 – 1.56; p<0.001, PLR: HR 1.78; 95% CI 1.45 – 2.17; p<0.001.
Conclusions
NLR, PLR, and LMR can be considered as prognostic biomarkers in ovarian cancer. Further studies are needed to re-evaluate these findings in the Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.G.P. Supadmanaba.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract